107 related articles for article (PubMed ID: 12576323)
1. Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation.
Sexl V; Kovacic B; Piekorz R; Moriggl R; Stoiber D; Hoffmeyer A; Liebminger R; Kudlacek O; Weisz E; Rothammer K; Ihle JN
Blood; 2003 Jun; 101(12):4937-43. PubMed ID: 12576323
[TBL] [Abstract][Full Text] [Related]
2. Functional involvement of Akt signaling downstream of Jak1 in v-Abl-induced activation of hematopoietic cells.
Oki S; Limnander A; Danial NN; Rothman PB
Blood; 2002 Aug; 100(3):966-73. PubMed ID: 12130510
[TBL] [Abstract][Full Text] [Related]
3. Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation.
Danial NN; Losman JA; Lu T; Yip N; Krishnan K; Krolewski J; Goff SP; Wang JY; Rothman PB
Mol Cell Biol; 1998 Nov; 18(11):6795-804. PubMed ID: 9774693
[TBL] [Abstract][Full Text] [Related]
4. Jak-STAT signaling induced by the v-abl oncogene.
Danial NN; Pernis A; Rothman PB
Science; 1995 Sep; 269(5232):1875-7. PubMed ID: 7569929
[TBL] [Abstract][Full Text] [Related]
5. IL-7 reconstitutes multiple aspects of v-Abl-mediated signaling.
Banerjee A; Rothman P
J Immunol; 1998 Nov; 161(9):4611-7. PubMed ID: 9794389
[TBL] [Abstract][Full Text] [Related]
6. Partial human Janus kinase 1 deficiency predominantly impairs responses to interferon gamma and intracellular control of mycobacteria.
Daza-Cajigal V; Albuquerque AS; Young DF; Ciancanelli MJ; Moulding D; Angulo I; Jeanne-Julien V; Rosain J; Minskaia E; Casanova JL; Boisson-Dupuis S; Bustamante J; Randall RE; McHugh TD; Thrasher AJ; Burns SO
Front Immunol; 2022; 13():888427. PubMed ID: 36159783
[TBL] [Abstract][Full Text] [Related]
7. Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene.
Jacobsen EA; Ananieva O; Brown ML; Chang Y
J Immunol; 2006 Jun; 176(11):6831-8. PubMed ID: 16709843
[TBL] [Abstract][Full Text] [Related]
8. In vitro transformation of murine pro-B and pre-B cells by v-mpl, a truncated form of a cytokine receptor.
Fichelson S; Vigon I; Dusanter I; Charon M; Velu T; Baillou C; Gisselbrecht S; Lemoine FM
J Immunol; 1995 Feb; 154(4):1577-86. PubMed ID: 7836743
[TBL] [Abstract][Full Text] [Related]
9. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
[TBL] [Abstract][Full Text] [Related]
10. Differential role of Janus family kinases (JAKs) in interferon-gamma-induced lung epithelial ICAM-1 expression: involving protein interactions between JAKs, phospholipase Cgamma, c-Src, and STAT1.
Chang YJ; Holtzman MJ; Chen CC
Mol Pharmacol; 2004 Mar; 65(3):589-98. PubMed ID: 14978237
[TBL] [Abstract][Full Text] [Related]
11. Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins.
Shuai K; Ziemiecki A; Wilks AF; Harpur AG; Sadowski HB; Gilman MZ; Darnell JE
Nature; 1993 Dec; 366(6455):580-3. PubMed ID: 7504784
[TBL] [Abstract][Full Text] [Related]
12. p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo.
Zou X; Cong F; Coutts M; Cattoretti G; Goff SP; Calame K
Mol Cell Biol; 2000 Jan; 20(2):628-33. PubMed ID: 10611241
[TBL] [Abstract][Full Text] [Related]
13. Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state.
Briscoe J; Rogers NC; Witthuhn BA; Watling D; Harpur AG; Wilks AF; Stark GR; Ihle JN; Kerr IM
EMBO J; 1996 Feb; 15(4):799-809. PubMed ID: 8631301
[TBL] [Abstract][Full Text] [Related]
14. Interferon-induced nuclear signalling by Jak protein tyrosine kinases.
Silvennoinen O; Ihle JN; Schlessinger J; Levy DE
Nature; 1993 Dec; 366(6455):583-5. PubMed ID: 7504785
[TBL] [Abstract][Full Text] [Related]
15. A small molecule Abl kinase inhibitor induces differentiation of Abelson virus-transformed pre-B cell lines.
Muljo SA; Schlissel MS
Nat Immunol; 2003 Jan; 4(1):31-7. PubMed ID: 12469118
[TBL] [Abstract][Full Text] [Related]
16. Interferon-gamma-induced MHC class I expression and defects in Jak/Stat signalling in methylcholanthrene-induced sarcomas.
Svane IM; Engel AM; Nielsen M; Werdelin O
Scand J Immunol; 1997 Oct; 46(4):379-87. PubMed ID: 9350289
[TBL] [Abstract][Full Text] [Related]
17. Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain.
Mainville CA; Parmar K; Unnikrishnan I; Gong L; Raffel GD; Rosenberg N
J Virol; 2001 Feb; 75(4):1816-23. PubMed ID: 11160680
[TBL] [Abstract][Full Text] [Related]
18. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression.
Dunn GP; Sheehan KC; Old LJ; Schreiber RD
Cancer Res; 2005 Apr; 65(8):3447-53. PubMed ID: 15833880
[TBL] [Abstract][Full Text] [Related]
19. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.
Dovhey SE; Ghosh NS; Wright KL
Cancer Res; 2000 Oct; 60(20):5789-96. PubMed ID: 11059775
[TBL] [Abstract][Full Text] [Related]
20. Active Akt and functional p53 modulate apoptosis in Abelson virus-transformed pre-B cells.
Gong L; Unnikrishnan I; Raghavan A; Parmar K; Rosenberg N
J Virol; 2004 Feb; 78(4):1636-44. PubMed ID: 14747529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
